Compare · CRDF vs IKNA
CRDF vs IKNA
Side-by-side comparison of Cardiff Oncology Inc. (CRDF) and Ikena Oncology Inc. (IKNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRDF and IKNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- IKNA is the larger of the two at $339.0M, about 4.1x CRDF ($82.7M).
- Over the past year, CRDF is down 61.6% and IKNA is up 3.6% - IKNA leads by 65.2 points.
- CRDF has hit the wire 13 times in the past 4 weeks while IKNA has been quiet.
- CRDF has more recent analyst coverage (13 ratings vs 5 for IKNA).
- Company
- Cardiff Oncology Inc.
- Ikena Oncology Inc.
- Price
- $1.22+2.97%
- $1.42+2.90%
- Market cap
- $82.7M
- $339.0M
- 1M return
- -30.57%
- +6.77%
- 1Y return
- -61.55%
- +3.65%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 13
- 0
- Recent ratings
- 13
- 5
Cardiff Oncology Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Ikena Oncology Inc.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Latest CRDF
- Chief Executive Officer Mohindru Mani bought $29,891 worth of shares (24,703 units at $1.21) (SEC Form 4)
- Director Pace Gary W bought $36,600 worth of shares (30,000 units at $1.22), increasing direct ownership by 2% to 1,356,376 units (SEC Form 4)
- SEC Form 4 filed by Director Tannenbaum Renee P
- SEC Form 4 filed by Director Pace Gary W
- SEC Form 4 filed by Director Markin Rodney S
- SEC Form 4 filed by Director White Lale
- SEC Form 4 filed by Director Armitage James O
- Cardiff Oncology downgraded by Craig Hallum with a new price target
- Cardiff Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
Latest IKNA
- Ikena Oncology Inc. filed SEC Form 8-K: Leadership Update, Other Events
- SEC Form 4 filed by Chief Executive Officer Yarema Kristin
- Director Orbimed Advisors Llc was granted 83,611 shares (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.
- Director Bonita David P converted options into 379 shares and bought $2,499,969 worth of shares (83,611 units at $29.90) (SEC Form 4)
- Director Stampacchia Otello converted options into 379 shares and bought $7,999,924 worth of shares (267,556 units at $29.90) (SEC Form 4)
- Chief Financial Officer Marango Jotin was granted 15,776 shares and covered exercise/tax liability with 4,630 shares (SEC Form 4)
- Principal Accounting Officer Butler Erin was granted 3,051 shares (SEC Form 4)
- SEC Form 3 filed by new insider Butler Erin
- SEC Form 3 filed by new insider Yarema Kristin